Stand Up To Cancer has announced three Research Teams focused on bringing new therapies to clinical trials for the treatment of gastroesophageal cancer.
Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed “prognostic modules,” that significantly influence the progression of 32 different types of cancer.
Investigators from the UCLA Health Jonsson Comprehensive Cancer Center have developed an artificial intelligence model based on epigenetic factors that is able to predict patient outcomes successfully across multiple cancer types.
The American Society for Radiation Oncology has issued a clinical guideline on partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ.
The Association of Community Cancer Centers has released consensus-based Oncology Financial Advocacy Services Guidelines, a comprehensive framework developed to aid cancer programs and practices deliver services to patients that prevent, detect, and mitigate financial hardship during cancer care.
Oral nicotine pouches, a tobacco leaf-free product marketed as an alternative to cigarettes, do little to curb current smokers’ nicotine cravings, according to a study.
FDA approved Keytruda (pembrolizumab) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.
FDA approved Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
FDA approved Truqap (capivasertib) with fulvestrant for adult patients with hormone receptor-positive, human epidermal growth factor receptor-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
FDA has granted approval for the HistoSonics’ Edison histotripsy device to treat liver tumors.
